Aligos Cash And Short Term Investments from 2010 to 2024
| ALGS Stock | USD 22.99 1.64 7.68% |
Cash And Short Term Investments | First Reported 2019-03-31 | Previous Quarter 94.6 M | Current Value 74.9 M | Quarterly Volatility 53.9 M |
Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 834.8 K, Net Interest Income of 1.3 M or Interest Income of 1 M, as well as many indicators such as Price To Sales Ratio of 25.26, Dividend Yield of 0.0 or PTB Ratio of 4.71. Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.
Aligos | Cash And Short Term Investments |
Latest Aligos Therapeutics' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Aligos Therapeutics over the last few years. Short Term Investments is an account in the current assets section of Aligos Therapeutics balance sheet. This account contains Aligos Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Aligos Therapeutics fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Aligos Therapeutics' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Aligos Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 119,793,070 | |
| Geometric Mean | 113,318,595 | |
| Coefficient Of Variation | 38.83 | |
| Mean Deviation | 35,013,293 | |
| Median | 90,852,000 | |
| Standard Deviation | 46,511,946 | |
| Sample Variance | 2163.4T | |
| Range | 152.7M | |
| R-Value | 0.65 | |
| Mean Square Error | 1359.1T | |
| R-Squared | 0.42 | |
| Significance | 0.01 | |
| Slope | 6,713,091 | |
| Total Sum of Squares | 30287.1T |
Aligos Cash And Short Term Investments History
About Aligos Therapeutics Financial Statements
Aligos Therapeutics shareholders use historical fundamental indicators, such as Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 135.7 M | 165.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.